Cvp Sociedade De Gestao Hospitalar S.A.

Research site

Portugal Rua Duarte Galvao 54, 1549-008 Lisbon, Portugal

3 trials recruiting
Atrial fibrillation · Cardiovascular disorder · Hypertension
Adult patients

About Specializations

Cvp Sociedade De Gestao Hospitalar S.A. in Lisbon, Portugal specialises in clinical trials of conditions such as Atrial fibrillation, Cardiovascular disorder, Hypertension, COVID-19 immunisation, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The research site concentrates on cardiovascular disease investigations, enrolling participants with established disease, high cardiovascular risk, hypertension, and type 2 diabetes. Studies are designed to evaluate new drug combinations and novel peptide agents to lower the incidence of major cardiac events.

Combination therapy with vicadrostat and empagliflozin
Zilebesiran peptide treatment for uncontrolled hypertension
Outcomes research in high‑risk cardiovascular populations
Reduction of heart‑failure hospitalizations
Interplay between metabolic disorders and cardiac risk

Ongoing work at Cvp Sociedade De Gestao Hospitalar S.A. strives to improve survival and quality of life for patients with type 2 diabetes and hypertension through innovative therapeutic strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Rua Duarte Galvao 541549-008 LisbonPortugal

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 10

More sites in Lisbon Portugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Obesity+1

Recruiting

Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

Investigational

Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

Portugal

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:REGN7508
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites